{"id":10099,"date":"2026-05-18T06:23:05","date_gmt":"2026-05-18T04:23:05","guid":{"rendered":"https:\/\/nexxusbio.com\/?p=10099"},"modified":"2026-08-10T16:50:49","modified_gmt":"2026-08-10T14:50:49","slug":"retatrutide-triple-agonist-glp1-gip-glukagon","status":"publish","type":"post","link":"https:\/\/nexxusbio.com\/en\/retatrutide-triple-agonist-glp1-gip-glukagon\/","title":{"rendered":"Retatrutide research: GIP, GLP-1 and glucagon receptors"},"content":{"rendered":"<p><strong>Retatrutide research<\/strong> It focuses on the experimental molecule LY3437943, which combines agonist activity on GIP, GLP-1 and glucagon receptors in a single molecular structure. This receptor profile is the reason why retatrutide is being studied as a model of multiple incretin and glucagon signaling.<\/p>\n<p>When interpreting available literature, it is important to distinguish between <strong>receptor pharmacology of retatrutide, material used in Eli Lilly clinical studies, and separate research-grade laboratory material<\/strong>. The results of a clinical trial with one investigational formulation cannot be automatically attributed to another commercially available sample.<\/p>\n<div style=\"background: #eef7fc; border-left: 4px solid #55a7d9; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>In short:<\/strong> Retatrutide (LY3437943) is an investigational agonist of three receptor systems \u2013 GIPR, GLP-1R and GCGR. The research includes receptor signaling, metabolic mechanisms and extensive clinical development. As of August 2026, Phase 2 data and part of Phase 3 data have been published, with further studies ongoing. Retatrutide is not approved for routine public use.<\/div>\n<div style=\"background: #f7f9fb; border: 1px solid #e1e7ec; padding: 20px 24px; margin: 25px 0; border-radius: 6px;\"><strong>Contents of the article<\/strong><\/p>\n<ul style=\"margin: 12px 0 0 20px;\">\n<li><a href=\"#co-je-retatrutide\">What is Retatrutide?<\/a><\/li>\n<li><a href=\"#triple-receptor\">Why is it called a triple receptor agonist?<\/a><\/li>\n<li><a href=\"#gipr\">GIP receptor \u2013 GIPR<\/a><\/li>\n<li><a href=\"#glp1r\">GLP-1 receptor \u2013 GLP-1R<\/a><\/li>\n<li><a href=\"#gcgr\">Glucagon receptor \u2013 GCGR<\/a><\/li>\n<li><a href=\"#receptorova-integracia\">Integrated receptor signaling<\/a><\/li>\n<li><a href=\"#faza2-retatrutide\">Phase 2 and first extensive clinical data<\/a><\/li>\n<li><a href=\"#faza3-retatrutide\">Phase 3 in 2026<\/a><\/li>\n<li><a href=\"#uroven-dokazov-retatrutide\">How to distinguish the level of evidence?<\/a><\/li>\n<li><a href=\"#research-grade-retatrutide\">Retatrutide of research grade and analytical documentation<\/a><\/li>\n<li><a href=\"#skladovanie-retatrutide\">Storage of laboratory materials<\/a><\/li>\n<li><a href=\"#limity-retatrutide\">What does the available research not show?<\/a><\/li>\n<li><a href=\"#faq-retatrutide\">FAQ<\/a><\/li>\n<li><a href=\"#zdroje-retatrutide\">Scientific and official sources<\/a><\/li>\n<\/ul>\n<\/div>\n<h2 id=\"co-je-retatrutide\">What is Retatrutide?<\/h2>\n<p><strong>Retatrutide<\/strong>, referred to during development as <strong>LY3437943<\/strong>, is an investigational peptide molecule developed as an agonist of three hormone receptor systems:<\/p>\n<ul>\n<li>GIP receptor \u2013 GIPR,<\/li>\n<li>GLP-1 receptor \u2013 GLP-1R,<\/li>\n<li>glucagon receptor \u2013 GCGR.<\/li>\n<\/ul>\n<p>It is precisely the combination of these three receptor activities in one molecule that distinguishes retatrutide from agonists targeting only one or two receptor systems.<\/p>\n<p>The development designation LY3437943 is therefore frequently found in scientific publications and clinical study registries together with the name retatrutide.<\/p>\n<p>Official overview:<\/p>\n<p><a href=\"https:\/\/www.lilly.com\/news\/stories\/what-to-know-about-retatrutide\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Eli Lilly \u2013 What to know about retatrutide<\/strong><\/a><\/p>\n<h2 id=\"triple-receptor\">Why is Retatrutide referred to as a triple receptor agonist?<\/h2>\n<p>The concept <strong>triple receptor agonist<\/strong> It describes the receptor pharmacology of the molecule. This means that retatrutide can experimentally activate three different receptors.<\/p>\n<div style=\"overflow-x: auto; margin: 25px 0;\">\n<table style=\"width: 100%; border-collapse: collapse; background: #eef7fc; border: 1px solid #c9e3f2;\">\n<thead>\n<tr style=\"background: #dceff9;\">\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Receptor<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Abbreviations<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Research context<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Glucose-dependent insulinotropic polypeptide receptor<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">GIPR<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Incretin and metabolic signaling.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Glucagon-like peptide-1 receptor<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">GLP-1R<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Incretin, neuroendocrine and metabolic signaling.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Glucagon receptor<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">GCGR<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Glucagon and hepatic metabolic signaling.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Retatrutide<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">LY3437943<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Experimental integration of all three receptor systems.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>The term \u201eGLP-3\u201c is sometimes used in the media. However, this is not the scientific name of the new hormone class. It is only an informal name for the triple receptor agonist.<\/p>\n<h2 id=\"gipr\">GIP receptor \u2013 GIPR<\/h2>\n<p><strong>GIPR<\/strong> G-protein receptor is activated by the natural hormone GIP. It belongs to a group of receptors involved in incretin signaling.<\/p>\n<p>In retatrutide, GIPR is studied as one of the three receptor components of a common pharmacological profile. However, it is necessary to evaluate the resulting molecule mechanistically as an integrated system and not as a simple sum of three separate agonists.<\/p>\n<h2 id=\"glp1r\">GLP-1 receptor \u2013 GLP-1R<\/h2>\n<p><strong>GLP-1R<\/strong> It is another G protein receptor and is among the most intensively studied incretin receptors.<\/p>\n<p>Retatrutide activates GLP-1R along with GIPR and GCGR. It is the current receptor activity that is the subject of pharmacological research and distinguishes this molecule from selective GLP-1 receptor agonists.<\/p>\n<h2 id=\"gcgr\">Glucagon receptor \u2013 GCGR<\/h2>\n<p><strong>GCGR<\/strong> It is a receptor for the natural hormone glucagon. It is significantly present, for example, in liver tissue and participates in the regulation of several metabolic processes.<\/p>\n<p>The incorporation of agonist activity on GCGR into a single molecule together with GIPR and GLP-1R is among the characteristic pharmacological properties of retatrutide.<\/p>\n<div style=\"background: #fff8dc; border: 1px solid #eadb99; border-left: 5px solid #d6b94c; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>Important interpretative note:<\/strong><\/p>\n<p>The activation of a specific receptor is a mechanistic pharmacological property. In itself, it does not demonstrate the health benefit or safety of standalone research-grade material.<\/p><\/div>\n<h2 id=\"receptorova-integracia\">Integrated receptor signaling<\/h2>\n<p>The most interesting scientific question regarding retatrutide is not only the activation of individual receptors, but also their interaction with each other. <strong>Combined signaling in a single molecule<\/strong>.<\/p>\n<p>The resulting biological response may depend on:<\/p>\n<ul>\n<li>the relative activity of the molecule on individual receptors,<\/li>\n<li>expression of receptors in a specific experimental tissue,<\/li>\n<li>concentration of the experimental substance,<\/li>\n<li>duration of receptor exposure,<\/li>\n<li>and a physiological or experimental model.<\/li>\n<\/ul>\n<p>Therefore, it is not accurate to describe retatrutide solely as \u201estronger GLP-1\u201c. This is a separate experimental receptor profile.<\/p>\n<h2 id=\"faza2-retatrutide\">Phase 2 and first extensive clinical data<\/h2>\n<p>A significant milestone was the randomized, double-blind Phase 2 study published in 2023 <em>New England Journal of Medicine<\/em>.<\/p>\n<p>The study examined adults with obesity or overweight with another defined risk factor and compared multiple dose groups of investigational retatrutide with placebo.<\/p>\n<p>The authors primarily evaluated changes in body weight, safety parameters, and adverse events during the controlled clinical protocol.<\/p>\n<p>Primary source:<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Jastreboff et al. \u2013 Retatrutide, a triple-hormone receptor agonist for obesity \u2013 a Phase 2 trial<\/strong><\/a><\/p>\n<p>This is clinical research of an investigational drug produced and controlled for a specific clinical study. The results of this work cannot be used as evidence of the properties of a standalone research-grade product.<\/p>\n<h2 id=\"faza3-retatrutide\">Phase 3 in 2026<\/h2>\n<p>As of August 2026, the clinical development of retatrutide is already in Phase 3 and includes several program studies. <strong>TRIUMPH<\/strong> a <strong>TRANSCEND-T2D<\/strong>.<\/p>\n<p>One of the important changes compared to previous reviews is that the first phase 3 has already been published in a peer-reviewed journal.<\/p>\n<h3>TRANSCEND-T2D-1<\/h3>\n<p>The randomized, double-blind phase 3 TRANSCEND-T2D-1 study examined retatrutide in adults with type 2 diabetes and insufficient glycemic control with dietary and lifestyle interventions.<\/p>\n<p>The results were published in a journal in 2026. <em>The Lancet<\/em>.<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42250575\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Bajaj et al. \u2013 TRANSCEND-T2D-1, phase 3 trial<\/strong><\/a><\/p>\n<h3>TRIUMPH-1<\/h3>\n<p>TRIUMPH-1 is a Phase 3 trial in participants with obesity or overweight without type 2 diabetes. The ClinicalTrials.gov registry lists it as completed, involving more than 2,000 participants.<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ClinicalTrials.gov \u2013 TRIUMPH-1, NCT05929066<\/strong><\/a><\/p>\n<h3>TRIUMPH-2 and TRIUMPH-3<\/h3>\n<p>The other 3 phases study populations with type 2 diabetes and obesity or overweight, and separately a population with severe obesity and established cardiovascular disease.<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929079\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ClinicalTrials.gov \u2013 TRIUMPH-2, NCT05929079<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05882045\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ClinicalTrials.gov \u2013 TRIUMPH-3, NCT05882045<\/strong><\/a><\/p>\n<p>In 2026, Lilly published the results of several Phase 3 studies. However, when conducting a scientific evaluation, it is appropriate to distinguish between: <strong>with a corporate heat-related announcement, conference presentation and a full-fledged reviewed publication<\/strong>.<\/p>\n<div style=\"overflow-x: auto; margin: 25px 0;\">\n<table style=\"width: 100%; border-collapse: collapse; background: #eef7fc; border: 1px solid #c9e3f2;\">\n<thead>\n<tr style=\"background: #dceff9;\">\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Research program<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Status \/ data type until August 2026<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Interpretation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Phase 2 \u2013 NEJM<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Reviewed clinical publication<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Controlled clinical data for the investigational product.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>TRANSCEND-T2D-1<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Phase 3, published in The Lancet<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">The reviewed data of a specific clinical population.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>TRIUMPH-1<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Phase 3 completed; program results published<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">It is necessary to distinguish between the register, the presented data, and the final publication.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>TRIUMPH-2 \/ TRIUMPH-3<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Phase 3; topline data published by the sponsor<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Not all detailed results need to be available at the same time in the reviewed publication.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>TRIUMPH-Outcomes<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">The ongoing long-term Phase 3<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">The results will be available only after the study is completed.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 id=\"uroven-dokazov-retatrutide\">How to distinguish the level of evidence?<\/h2>\n<p>Retatrutide is a good example of a molecule where there are several completely different types of data.<\/p>\n<div style=\"overflow-x: auto; margin: 25px 0;\">\n<table style=\"width: 100%; border-collapse: collapse; background: #eef7fc; border: 1px solid #c9e3f2;\">\n<thead>\n<tr style=\"background: #dceff9;\">\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">Data type<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">What they can show<\/th>\n<th style=\"padding: 12px; border: 1px solid #c9e3f2; text-align: left;\">What they do not prove<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Receptor experiments<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Activity on GIPR, GLP-1R and GCGR.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">The clinical outcome of a particular person.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Preclinical models<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Mechanisms in cellular or animal systems.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Automatic efficacy or safety in humans.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Randomized clinical studies<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Results of an exploratory formulation in a precisely defined population.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Properties of another commercially available research-grade material.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>Topline results of the sponsor<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Preliminary summary of the main endpoints.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Compensation for a complete reviewed publication.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\"><strong>COA research-grade batches<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">The identity, chromatographic purity, or quantity of a specific sample according to the method used.<\/td>\n<td style=\"padding: 12px; border: 1px solid #c9e3f2;\">Clinical safety or therapeutic efficacy.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Is Retatrutide an approved drug?<\/h2>\n<p>Retatrutide remains available until August 2026 <strong>investigative molecule<\/strong>. Eli Lilly states that it has not yet been approved by regulatory authorities for routine public use and its safety and efficacy continue to be evaluated in clinical development.<\/p>\n<p>At the same time, the company announced in 2026 its intention to submit a regulatory application in 2027.<\/p>\n<p>Current official source:<\/p>\n<p><a href=\"https:\/\/www.lilly.com\/news\/stories\/what-to-know-about-retatrutide\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Eli Lilly \u2013 current state of development of retatrutide<\/strong><\/a><\/p>\n<div style=\"background: #fff8dc; border: 1px solid #eadb99; border-left: 5px solid #d6b94c; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>Important distinction:<\/strong><\/p>\n<p>The clinical investigational product used in Eli Lilly studies cannot be automatically considered to be identical to research-grade material sold by an independent laboratory supplier. The same molecular name does not demonstrate a match in formulation, purity, quantity, production, or quality parameters.<\/p><\/div>\n<h2 id=\"research-grade-retatrutide\">Retatrutide of research grade and analytical documentation<\/h2>\n<p>For the laboratory customer, it is necessary to separate the clinical literature from the analytical evaluation of a specific research-grade batch.<\/p>\n<p>The relevant parameters of a specific laboratory sample include:<\/p>\n<ul>\n<li>molecular identity,<\/li>\n<li>chromatographic profile,<\/li>\n<li>HPLC area purity,<\/li>\n<li>quantitative determination of the content,<\/li>\n<li>batch number or lot number,<\/li>\n<li>the used reference substance,<\/li>\n<li>the analytical method used,<\/li>\n<li>and the traceability of the COA to a specific batch.<\/li>\n<\/ul>\n<div style=\"background: #eef7fc; border-left: 4px solid #55a7d9; padding: 18px 20px; margin: 25px 0; border-radius: 6px;\"><strong>Analytical note:<\/strong> HPLC area purity is not identical to the amount of retatrutide in the vial. Mass spectrometry can help identify the molecular signal, but by itself it does not replace the quantitative determination of the content. Each analytical result should be interpreted according to the specific method and specific batch.<\/div>\n<p>More about batch evaluation, COA and analytical documentation can be found in the article <a href=\"https:\/\/nexxusbio.com\/en\/7-kriterii-vyberu-peptidoveho-dodavatela\/\"><strong>7 criteria for selecting a peptide supplier<\/strong><\/a>.<\/p>\n<p>Available analytical documents can also be verified in the section <a href=\"https:\/\/nexxusbio.com\/en\/coa\/\"><strong>COA and analytical documentation<\/strong><\/a>.<\/p>\n<h2 id=\"skladovanie-retatrutide\">Storage of laboratory materials<\/h2>\n<p>Keep research-grade material at <strong>\u201320 \u00b0C or 2\u20138 \u00b0C according to the label and the CoA of the specific batch<\/strong>. In the case of a specific sample, the batch-specific conditions specified in the technical documentation and on the product label always take precedence.<\/p>\n<h2 id=\"limity-retatrutide\">What does the available research not show?<\/h2>\n<p>Despite extensive clinical development, it is necessary to rigorously separate data on investigational drug from marketing research-grade material.<\/p>\n<p>The available data by themselves do not show:<\/p>\n<ul>\n<li>that the research-grade sample is the same material as the investigational product of Eli Lilly,<\/li>\n<li>clinical safety of a standalone commercial research-grade material,<\/li>\n<li>that the results of one dose or clinical group can be extrapolated to other experimental material,<\/li>\n<li>that receptor activity automatically means a specific health benefit,<\/li>\n<li>that the sponsor's result of the heat is identical to the complete peer-reviewed publication,<\/li>\n<li>that high chromatographic purity constitutes evidence of clinical efficacy,<\/li>\n<li>that the very name \u201eretatrutide\u201c confirms the origin, manufacturer, or pharmaceutical equivalence of a specific sample.<\/li>\n<\/ul>\n<p>Therefore, for a research-grade informational or product page, it is not appropriate to use consumer-oriented terms such as \u201erevolutionary drug\u201c, \u201eweight loss peptide\u201c, \u201estrongest fat burner\u201c, \u201eOzempic replacement\u201c, or other claims aimed at personal health outcomes.<\/p>\n<h2>How to critically read studies on Retatrutide?<\/h2>\n<p>It is advisable to verify with each source:<\/p>\n<ul>\n<li>whether it is receptor-based, preclinical or clinical research,<\/li>\n<li>the phase of a clinical study,<\/li>\n<li>the studied population,<\/li>\n<li>primary and secondary endpoints,<\/li>\n<li>whether the results are just heat or already reviewed,<\/li>\n<li>whether the publication is a primary work or a secondary review,<\/li>\n<li>and whether it is an investigative product from the sponsor of the clinical study or independent research-grade material.<\/li>\n<\/ul>\n<h2 id=\"faq-retatrutide\">FAQ \u2013 Retatrutide research<\/h2>\n<h3>What is Retatrutide?<\/h3>\n<p>Retatrutide, developed as LY3437943, is an investigational molecule with agonist activity on the GIPR, GLP-1R and GCGR receptors.<\/p>\n<h3>What does a triple receptor agonist mean?<\/h3>\n<p>This means that one molecule activates three receptor systems \u2013 GIP, GLP-1 and the glucagon receptor. This is a pharmacological description of the receptor profile.<\/p>\n<h3>Is Retatrutide GLP-3?<\/h3>\n<p>No. \u201eGLP-3\u201c is an informal media term and is not a scientific hormonal classification. Retatrutide is more accurately referred to as an agonist of GIPR, GLP-1R and GCGR.<\/p>\n<h3>Are there Phase 3 studies?<\/h3>\n<p>Yes. As of August 2026, a large Phase 3 program, TRANSCEND-T2D-1, has already been published in a peer-reviewed journal, and further studies of the TRIUMPH program are complete or ongoing.<\/p>\n<h3>Is Retatrutide approved for regular use?<\/h3>\n<p>No. Until August 2026, it remains an investigational molecule and clinical development continues.<\/p>\n<h3>Is the research-grade Retatrutide the same as the product used in clinical studies?<\/h3>\n<p>Such equivalence cannot be assumed. The same molecular name does not confirm the same manufacturer, formulation, batch, purity, quantity, or pharmaceutical quality.<\/p>\n<h3>What does HPLC purity mean?<\/h3>\n<p>HPLC area purity describes the relative representation of chromatographic signals within a specific analytical method. It is not identical to the amount of material in the vial and does not represent evidence of clinical safety or efficacy.<\/p>\n<h3>How is research-grade Retatrutide stored?<\/h3>\n<p>According to the label and CoA of the specific batch, typically when <strong>\u201320 \u00b0C or 2\u20138 \u00b0C<\/strong>, If the technical documentation of a specific product states so.<\/p>\n<p>You can find more professional articles in the section <a href=\"https:\/\/nexxusbio.com\/en\/category\/peptide-analysis\/\"><strong>Research on peptides<\/strong><\/a>.<\/p>\n<h2 id=\"zdroje-retatrutide\">Scientific and official sources<\/h2>\n<ol>\n<li>Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.<br \/>\n<em>Retatrutide, an agonist of the triple-receptor for obesity \u2013 a Phase 2 trial.<\/em><br \/>\nNew England Journal of Medicine. 2023.<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed<\/a><\/li>\n<li>Bajaj HS, Welch M, Shah P, et al.<br \/>\n<em>Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycemic control with diet and exercise \u2013 TRANSCEND-T2D-1.<\/em><br \/>\nThe Lancet. 2026.<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42250575\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed<\/a><\/li>\n<li>Giblin K, Kaplan LM, Somers VK, et al.<br \/>\n<em>Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials.<\/em><br \/>\nDiabetes, Obesity and Metabolism. 2026.<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41090431\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed<\/a><\/li>\n<li>ClinicalTrials.gov.<br \/>\n<em>TRIUMPH-1 \u2013 NCT05929066.<\/em><br \/>\n<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\" target=\"_blank\" rel=\"noopener noreferrer\">ClinicalTrials.gov<\/a><\/li>\n<li>ClinicalTrials.gov.<br \/>\n<em>TRIUMPH-2 \u2013 NCT05929079.<\/em><br \/>\n<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929079\" target=\"_blank\" rel=\"noopener noreferrer\">ClinicalTrials.gov<\/a><\/li>\n<li>ClinicalTrials.gov.<br \/>\n<em>TRIUMPH-3 \u2013 NCT05882045.<\/em><br \/>\n<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05882045\" target=\"_blank\" rel=\"noopener noreferrer\">ClinicalTrials.gov<\/a><\/li>\n<li>ClinicalTrials.gov.<br \/>\n<em>TRIUMPH-Outcomes \u2013 NCT06383390.<\/em><br \/>\n<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06383390\" target=\"_blank\" rel=\"noopener noreferrer\">ClinicalTrials.gov<\/a><\/li>\n<li>Eli Lilly and Company.<br \/>\n<em>What to know about retatrutide.<\/em><br \/>\n<a href=\"https:\/\/www.lilly.com\/news\/stories\/what-to-know-about-retatrutide\" target=\"_blank\" rel=\"noopener noreferrer\">Eli Lilly<\/a><\/li>\n<\/ol>\n<div style=\"background: #fff8dc; border: 1px solid #eadb99; border-left: 5px solid #d6b94c; padding: 18px 20px; margin: 30px 0; border-radius: 6px;\"><strong>Important notice:<\/strong><\/p>\n<p>This article is for informational, educational, and scientific purposes only. The information describes receptor, molecular, preclinical, and clinical research data and does not constitute medical advice, diagnosis, prevention, or treatment instructions.<\/p>\n<p>The results of clinical studies with investigational retatrutide cannot be automatically transferred to standalone research-grade material from another manufacturer or supplier. The same molecular name does not indicate pharmaceutical equivalence.<\/p>\n<p>Retatrutide of research grade and other materials presented on the NEXXUS BIO website are intended solely for laboratory, analytical and scientific purposes (Research Use Only). They are not intended for human or veterinary use, consumption, personal application, diagnosis, prevention or treatment.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Retatrutide v\u00fdskum sa s\u00fastre\u010fuje na experiment\u00e1lnu molekulu LY3437943, ktor\u00e1 v jednej molekulovej \u0161trukt\u00fare kombinuje agonistick\u00fa aktivitu na receptoroch pre GIP,<\/p>","protected":false},"author":2,"featured_media":10770,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[194],"tags":[],"class_list":["post-10099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vyskum-peptidov"],"_links":{"self":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts\/10099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/comments?post=10099"}],"version-history":[{"count":9,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts\/10099\/revisions"}],"predecessor-version":[{"id":10771,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/posts\/10099\/revisions\/10771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/media\/10770"}],"wp:attachment":[{"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/media?parent=10099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/categories?post=10099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nexxusbio.com\/en\/wp-json\/wp\/v2\/tags?post=10099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}